What does Arvinas, Inc. do?
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein…
What is Arvinas, Inc.'s P/E and P/B ratio?
Arvinas, Inc. has a P/E ratio of 29.7 and a P/B ratio of 0.89.
What is Arvinas, Inc.'s debt-to-equity ratio?
Arvinas, Inc. has a debt-to-equity ratio of 0.01.
How much does Arvinas, Inc. owe compared with what it owns?
Arvinas, Inc. owes $0.17 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Arvinas, Inc.'s Positivity rank?
Arvinas, Inc. is ranked #1,208 of 6,775 companies globally and #227 of 4,000 in United States on PositoAI, with a Positivity Score of 23,165.
Does Arvinas, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Arvinas, Inc..
Where can I read the latest news about Arvinas, Inc.?
Recent headlines about Arvinas, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Arvinas, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Arvinas, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.